Influenza Immunization Protocol for Fluzone® High-Dose Quadrivalent

Purpose	Provide information and guidance for the Influenza Immunization Program in Nunavut.
Objective	To reduce morbidity and mortality secondary to Influenza infection.
Indication	FLUZONE® High-Dose Quadrivalent (FLUZONE® HD QIV) vaccine is indicated for active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine in adults 65 years of age and older.
Eligibility	FLUZONE® HD QIV is indicated for adults 65 years of age and older.
Product	FLUZONE® High-Dose Quadrivalent
Vaccine type	Quadrivalent Inactivated – split virus (for more information see references)
Vaccine components	**Active Ingredients:** Each 0.7 mL dose contains 60 µg HA of each of the four influenza strains (A/H3N2, A/H1N1, B/Yamagata like, and B/Victoria like). **Other Ingredients:** 0.7 mL dose: ≤ 350 µg octylphenol ethoxylate (Triton® X-100), ≤ 200 µg/mL formaldehyde and up to 0.7 mL sodium phosphate buffered isotonic sodium chloride solution.
Formats available	FLUZONE® HD QIV is available in packages of: 5 x 0.7 mL (single dose) syringes without attached needle. 10 x 0.7 mL (single dose) syringes without attached needle.
Manufacturer	Sanofi Pasteur Limited
Administration	Inspect for extraneous particulate matter and/or discolouration before use. If either of these conditions exist, the product should not be administered. **Shake the prefilled syringe well** to uniformly distribute the suspension before administering the dose. Administer the vaccine **intramuscularly**. The preferred site is the deltoid muscle. FLUZONE® HD QIV should not be administered into the buttocks.
Dose Series	The recommended dosage of FLUZONE® HD QIV is 1 dose of 0.7 mL, annually.
Booster Dose	N/A
Vaccine interchangeability	Nunavummiut who meet the eligibility criteria (e.g. 65 or older) with no contraindications have a choice to receive either FLUZONE® HD QIV or FLUZONE® QIV.
Concomitant Administration	FLUZONE® HD QIV may be given at the same time as other inactivated or live vaccines.

	Please take the opportunity to review COVID-19 immunization history and offer immunization to eligible individuals. Additionally, unimmunized adults over 50 years old who have not received pneumococcal polysaccharide vaccine (Pneumovax 23) may be offered this vaccine.
Contraindications	FLUZONE® HD QIV should not be administered to people who have had an anaphylactic reaction to a specific influenza immunization, or to any of the components of a specific influenza vaccine. Egg allergy is not a contraindication. An apparent allergic reaction to the vaccine or any other symptoms (e.g. throat constriction, difficulty swallowing) that raise concern regarding the safety of re- immunization; Severe lower respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours prior to influenza vaccine. Guillain-Barré syndrome (GBS) has been temporally associated with the administration of influenza vaccine. If GBS has occurred within 6 weeks following previous influenza vaccination, the decision to give FLUZONE® HD QIV should be based on careful consideration of the potential benefits and risks. Please consult the RCDC.
Precautions and Additional Notes	The National Advisory Committee on Immunization (NACI) has concluded that egg allergic individuals may be vaccinated against influenza using Quadrivalent Influenza Vaccine without a prior influenza vaccine skin test and with the full dose in any setting where vaccines are routinely administered. Persons with serious acute febrile illness usually should not be vaccinated until their symptoms have abated. Those with mild non-serious febrile illness (such as mild upper respiratory tract infections) may be given influenza vaccine.
Vaccine Supply and Distribution	Review section on vaccine ordering in the Policy and Procedure section of the Nunavut Drug Formulary.
Storage	Store in monitored vaccine refrigerator between 2°C and 8°C. Keep in original packaging. Protect from light. DO NOT FREEZE. Freezing destroys the active components of the vaccine. Follow cold chain protocol and inform RCDC and regional pharmacy for guidance if a cold chain break occurs.
Consent	Informed verbal consent must be obtained from the client and appropriately documented in Meditech prior to vaccination.
Anaphylaxis	Review the principles of the emergency management of anaphylaxis in the Nunavut Immunization Manual Section 3 (3.7). Further information can be found in: Anaphylaxis: Initial Management in Non-Hospital

	Settings, in the Canadian Immunization Guide.
Side Effects	Injection site: pain, tenderness, redness, swelling at injection site. Systemic: fever, fatigue, headache, malaise, and myalgia.
Reportable Adverse Events/Side Effects	Report all serious adverse events requiring medical attention, unusual/unexpected events, or medication errors to RCDC. Review section 3.5 Management and Reporting of Adverse Events in the Nunavut Immunization Manual.
Documentation	All immunizations given should be documented in the electronic record. Update recipient's Personal Immunization Record as requested.
Materials and Resources	All protocols and materials are available on the Department of Health website (www.gov.nu.ca/health) Nunavut Communicable Disease and Surveillance Manual: Influenza Public Health Protocol Nunavut Immunization Manual Fluzone High-Dose Quadrivalent Fact Sheet
References	1. FLUZONE® High-Dose Quadrivalent. Product Monograph. Sanofi Pasteur. April 19, 2022. Available at: 00072470.PDF (hres.ca)Public Health Agency of Canada. Canadian Immunization Guide – Evergreen Edition (2012). Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/index- eng.php 3. National Advisory Committee on Immunization (NACI) statement: Seasonal influenza vaccine for 2023-2024 - Canada.ca